Q2 2024 · 13F-HR
Propel Bio Management, LLCholdings as filed
Filed 2024-08-12 · accession 0001829126-24-005385
$154.2M
Reported value
24
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $30.7M | 19.9% | 6,567,858 | Common | SOLE |
| 72651A207 | PAGP | PLAINS GP HOLDINGS LP-CL | $25.8M | 16.8% | 1,372,360 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $12.2M | 7.92% | 2,087,139 | Common | SHARED |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS | $12.1M | 7.82% | 43,032 | Common | SHARED |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $11.5M | 7.48% | 2,453,092 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS I | $9.0M | 5.81% | 869,927 | Common | SHARED |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $7.7M | 4.99% | 327,752 | Common | SHARED |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $7.3M | 4.73% | 178,500 | Common | SHARED |
| 039697107 | ARDX | ARDELYX INC | $6.9M | 4.44% | 924,583 | Common | SHARED |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $5.3M | 3.43% | 1,248,044 | Common | SHARED |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $4.7M | 3.02% | 750,000 | Common | SHARED |
| 04746L104 | — | ATHIRA PHARMA INC | $4.0M | 2.57% | 1,492,792 | Common | SHARED |
| 879512309 | TSAT | TELESAT CORP | $3.3M | 2.16% | 365,781 | Common | SHARED |
| 92511W108 | — | VERRICA PHARMACEUTICALS I | $3.1M | 2.01% | 424,937 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $2.7M | 1.74% | 130,000 | Common | SHARED |
| 28249U204 | 72C | EIGER BIOPHARMACEUTICALS | $1.9M | 1.20% | 146,381 | Common | SHARED |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS IN | $1.7M | 1.11% | 83,259 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $1.7M | 1.09% | 56,359 | Common | SHARED |
| 486606106 | KYN | KAYNE ANDERSON ENERGY INF | $1.5M | 0.99% | 147,033 | Common | SHARED |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $774,800 | 0.50% | 260,000 | Common | SHARED |
| X9USDFIDT | — | FIDELITY INV MMTRSY 1 680 | $317,014 | 0.21% | 317,014 | Common | SHARED |
| 23256X100 | — | CYBIN INC | $230,350 | 0.15% | 850,000 | Common | SHARED |
| 00BNRR5C1 | — | MAAT PHARMA SACA | $9,752 | 0.01% | 1,362 | Common | SHARED |
| 169CVR016 | — | CHINOOK THERAPEUTICS | $9,750 | 0.01% | 79,357 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.